tiprankstipranks
Synairgen Prioritizes SNG001 Development, Eyes Phase 2 Trial
Company Announcements

Synairgen Prioritizes SNG001 Development, Eyes Phase 2 Trial

Synairgen (GB:SNG) has released an update.

Don't Miss our Black Friday Offers:

Synairgen plc has announced its preliminary financial results for 2023, highlighting a strategic focus on developing SNG001, a potential antiviral treatment for severe viral lung infections, with an upcoming Phase 2 trial targeted at mechanically ventilated patients. The company has reported a reduced operational loss and a strong cash position, indicating prudent cost control measures. Moreover, Synairgen continues to collaborate on the UNIVERSAL trial and remains open to future partnerships.

For further insights into GB:SNG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskSynairgen Expands Share Capital with New Issuance
TipRanks UK Auto-Generated NewsdeskSynairgen Appoints New Chairman, Advances Antiviral Treatment
TipRanks UK Auto-Generated NewsdeskSynairgen Prepares for Pivotal Phase 2 Trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App